239 related articles for article (PubMed ID: 35246429)
1. Nephrotic syndrome with minimal change disease after the Pfizer-BioNTech COVID-19 vaccine: two cases.
Hartley JL; Bailey N; Sharma A; Shawki H
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35246429
[TBL] [Abstract][Full Text] [Related]
2. Pediatric Minimal Change Disease and AKI following the Pfizer-BioNTech COVID-19 Vaccine: causal or incidental correlation?
Annicchiarico Petruzzelli L; Minale B; Serio V; De Luca A; Marino Marsilia G; Campione S; Diomedi Camassei F; D'Arcangelo R; Luongo I; Lepore L; Giannattasio P; Molino D; Pirro L; Lonardo MC; Malgieri G; Pecoraro C
G Ital Nefrol; 2022 Dec; 39(6):. PubMed ID: 36655832
[TBL] [Abstract][Full Text] [Related]
3. Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
Lebedev L; Sapojnikov M; Wechsler A; Varadi-Levi R; Zamir D; Tobar A; Levin-Iaina N; Fytlovich S; Yagil Y
Am J Kidney Dis; 2021 Jul; 78(1):142-145. PubMed ID: 33839200
[TBL] [Abstract][Full Text] [Related]
4. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine.
D'Agati VD; Kudose S; Bomback AS; Adamidis A; Tartini A
Kidney Int; 2021 Aug; 100(2):461-463. PubMed ID: 34000278
[No Abstract] [Full Text] [Related]
5. New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review.
Nakazawa E; Uchimura T; Hirai Y; Togashi H; Oyama Y; Inaba A; Shiga K; Ito S
CEN Case Rep; 2022 May; 11(2):242-246. PubMed ID: 34782983
[TBL] [Abstract][Full Text] [Related]
6. De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor.
Marinaki S; Kolovou K; Liapis G; Skalioti C; Tsiakas S; Boletis I
Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056345
[TBL] [Abstract][Full Text] [Related]
7. Minimal change disease following the Moderna COVID-19 vaccine: first case report.
Thappy S; Thalappil SR; Abbarh S; Al-Mashdali A; Akhtar M; Alkadi MM
BMC Nephrol; 2021 Nov; 22(1):376. PubMed ID: 34763669
[TBL] [Abstract][Full Text] [Related]
8. Exacerbation of Minimal Change Disease Following mRNA COVID-19 Vaccination.
Pirzadeh A; Emami S; Zuckerman JE; Nobakht N
Am J Case Rep; 2023 Nov; 24():e941621. PubMed ID: 37941318
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
10. New-onset Nephrotic Syndrome after Janssen COVID-19 Vaccination: a Case Report and Literature Review.
Lim JH; Han MH; Kim YJ; Kim MS; Jung HY; Choi JY; Cho JH; Kim CD; Kim YL; Park SH
J Korean Med Sci; 2021 Aug; 36(30):e218. PubMed ID: 34342187
[TBL] [Abstract][Full Text] [Related]
11. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
12. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
13. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
Maas RJ; Gianotten S; van der Meijden WAG
Am J Kidney Dis; 2021 Aug; 78(2):312. PubMed ID: 33992727
[No Abstract] [Full Text] [Related]
14. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
Komaba H; Wada T; Fukagawa M
Am J Kidney Dis; 2021 Sep; 78(3):469-470. PubMed ID: 34023417
[No Abstract] [Full Text] [Related]
15. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
16. Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine.
Giuffrida G; Condorelli A; Di Giorgio MA; Markovic U; Sciortino R; Nicolosi D; Di Raimondo F
Haematologica; 2022 Apr; 107(4):1008-1010. PubMed ID: 34382388
[No Abstract] [Full Text] [Related]
17. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report.
Leclerc S; Royal V; Lamarche C; Laurin LP
Am J Kidney Dis; 2021 Oct; 78(4):607-610. PubMed ID: 34242687
[TBL] [Abstract][Full Text] [Related]
18. Report of two cases of minimal change disease following vaccination for COVID -19.
Baskaran K; Cohen AWS; Weerasinghe N; Vilayur E
Nephrology (Carlton); 2022 Jan; 27(1):111-112. PubMed ID: 34779088
[No Abstract] [Full Text] [Related]
19. Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5-11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022.
Cortese MM; Taylor AW; Akinbami LJ; Thames-Allen A; Yousaf AR; Campbell AP; Maloney SA; Harrington TA; Anyalechi EG; Munshi D; Kamidani S; Curtis CR; McCormick DW; Staat MA; Edwards KM; Creech CB; Museru O; Marquez P; Thompson D; Su JR; Schlaudecker EP; Broder KR
J Infect Dis; 2023 Jul; 228(2):143-148. PubMed ID: 36821777
[TBL] [Abstract][Full Text] [Related]
20. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine.
Drago F; Ciccarese G; Guadagno A; Parodi A
J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e979-e981. PubMed ID: 35841285
[No Abstract] [Full Text] [Related]
[Next] [New Search]
